

## Special Issue

# Vaccines and Passive Immune Strategies in Veterinary Medicine

### Message from the Guest Editors

The aim of the issue will be to summarize the results and performances of the latest vaccines and passive immune therapies that are under development for animal diseases. We also invite data regarding the performance, stability and efficacy of products that have already been launched on the veterinary market. We also encourage authors to submit for publication their results from research teams working in the development of animals' models for vaccine potency testing. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following topics:

- Targeted subunit and VLP veterinary vaccines;
- mRNA and DNA vaccines for veterinary use;
- IgY therapies for animal diseases;
- Llama-derived nanobodies against animal diseases;
- Equine Fab antiserum to prevent and treat animal diseases.

### Guest Editors

Dr. Viviana Parreno

Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060, USA

Dr. Marina Bok

1. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires C1425FQB, Argentina

2. INCUINTA, CICVyA, Instituto Nacional de Tecnología Agropecuaria, De Los Reseros y Nicolás Repetto S/N, Buenos Aires 1686, Argentina

### Deadline for manuscript submissions

closed (30 November 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/175324](https://mdpi.com/si/175324)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).